NasdaqCM - Nasdaq Real Time Price • USD
Aileron Therapeutics, Inc. (ALRN)
As of 12:07 PM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
15,348.0000
15,348.0000
27,647.0000
26,605.0000
20,496.0000
Operating Income
-15,348.0000
-15,348.0000
-27,647.0000
-26,605.0000
-20,496.0000
Net Non Operating Interest Income Expense
400.0000
400.0000
300.0000
--
--
Other Income Expense
-728.0000
-728.0000
318.0000
441.0000
-700.0000
Pretax Income
-15,676.0000
-15,676.0000
-27,329.0000
-26,164.0000
-21,196.0000
Net Income Common Stockholders
-15,732.0000
-15,732.0000
-27,329.0000
-26,164.0000
-21,157.0000
Diluted NI Available to Com Stockholders
-15,732.0000
-15,732.0000
-27,329.0000
-26,164.0000
-21,157.0000
Basic EPS
-3.42
-3.42
-6.02
-5.89
-12.20
Diluted EPS
-3.42
-3.42
-6.02
-5.89
-12.20
Basic Average Shares
4,598.7150
4,598.7150
4,539.3180
4,440.3380
1,743.3340
Diluted Average Shares
4,598.7150
4,598.7150
4,539.3180
4,440.3380
1,743.3340
Total Operating Income as Reported
-16,276.0000
-16,276.0000
-27,647.0000
-26,605.0000
-20,496.0000
Total Expenses
15,348.0000
15,348.0000
27,647.0000
26,605.0000
20,496.0000
Net Income from Continuing & Discontinued Operation
-15,732.0000
-15,732.0000
-27,329.0000
-26,164.0000
-21,157.0000
Normalized Income
-15,004.0000
-15,004.0000
-27,329.0000
-26,164.0000
-21,257.0000
Interest Income
400.0000
400.0000
300.0000
--
--
Net Interest Income
400.0000
400.0000
300.0000
--
--
EBIT
-15,348.0000
-15,348.0000
-27,647.0000
-26,605.0000
-20,496.0000
EBITDA
-15,229.0000
-15,229.0000
-27,478.0000
-26,484.0000
-20,333.0000
Reconciled Depreciation
119.0000
119.0000
169.0000
121.0000
163.0000
Net Income from Continuing Operation Net Minority Interest
-15,732.0000
-15,732.0000
-27,329.0000
-26,164.0000
-21,157.0000
Total Unusual Items Excluding Goodwill
-728.0000
-728.0000
--
400.0000
100.0000
Total Unusual Items
-728.0000
-728.0000
--
400.0000
100.0000
Normalized EBITDA
-14,501.0000
-14,501.0000
-27,478.0000
-26,484.0000
-20,433.0000
12/31/2020 - 6/29/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BNTC Benitec Biopharma Inc.
7.00
+2.04%
BPTH Bio-Path Holdings, Inc.
2.6000
-3.15%
CHRO Chromocell Therapeutics Corporation
1.5127
-3.03%
NKGN NKGen Biotech, Inc.
1.7800
-3.80%
PALI Palisade Bio, Inc.
5.75
-2.87%
RANI Rani Therapeutics Holdings, Inc.
6.42
-4.02%
MLEC Moolec Science SA
1.4600
-15.61%
VNDA Vanda Pharmaceuticals Inc.
4.5900
-0.86%
PHIO Phio Pharmaceuticals Corp.
0.6904
-1.48%
TCON TRACON Pharmaceuticals, Inc.
1.8900
+2.16%